

A History as a Partner to Patients for over 100 years

The Daiichi Sankyo Group leverages its century-long strengths in Science & Technology (S&T) forged by its predecessors to continue to take on the challenge of creating advanced pharmaceutical products.

Harnessing S&T as the driving force, we will continue to create innovative pharmaceuticals and realizing Healthcare as a Service (Haas)* by developing both a total care ecosystem and a total care platform through collaboration with other companies as we work toward our 2030 Vision and thereby “contribute to the enrichment of quality of life around the world.”

* Haas refers to providing health and medical services that are optimized and tailored to each individual by utilizing a variety of data and advanced technologies.

Steps of our 5-year business plan



History as a pharma innovator (major products over the years)

- 1899** Launched **Taka-Diastase**, a digestive enzyme agent
- 1902** Adrenalin, an adrenal cortex hormone agent
- 1910** Dr. Umetaro Suzuki, a future Sankyo scientific adviser, established a foundation for the theory of vitamins
- 1915** Began domestic manufacturing of Salvarsan, a therapeutic drug for syphilis
- 1922** Began manufacturing of **Bosmin**, a vasoconstriction/ hemostasis and asthma medicine
- 1951** Manufactured **Chloromycetin**, the first antibiotic produced in Japan
- 1965** Launched **Transamin**, a hemostatic and anti-inflammatory agent
- 1985** **Tarivid**, a broad-spectrum oral antimicrobial agent
- 1986** **Loxonin**, an anti-inflammatory analgesic
- 1989** **Mevalotin**, hypercholesterolemia treatment
- 1993** **Cravif**, a broad-spectrum oral antimicrobial agent
- 2002** Olmesartan (**Olmetec** in Japan and Europe, **Benicar** in the United States), an antihypertensive agent

2009 Efient , an antiplatelet agent	2010 Inavir , anti-influenza treatment	2011 Lixiana , an anticoagulant	2016	2019 Tarlige , pain treatment	2020 Enhertu , an anti-cancer agent (HER2 directed antibody drug conjugate)
---	--	---	-------------	--	--

Transition of unmet medical needs throughout time




2030 Vision
Innovative Global Healthcare Company
Contributing to the Sustainable Development of Society



A society that has realized Haas

Source: Presentation document of Society 5.0 “A New Society Pioneered by Science and Technology Innovation” by the Cabinet Office



Creating innovative pharmaceuticals by leveraging our strengths in Science & Technology (S&T)

Realizing Healthcare as a Service through development of both a total care ecosystem and a total care platform